AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Scope & Guideline
Enhancing clinical outcomes through impactful research.
Introduction
Aims and Scopes
- Respiratory Diseases:
The journal addresses a wide range of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary hypertension, emphasizing both clinical and molecular research. - Critical Care Medicine:
The focus extends to critical care medicine, particularly the management of patients with acute respiratory distress syndrome (ARDS), sepsis, and other critical conditions, highlighting advancements in intensive care practices. - Molecular and Cellular Biology:
Research published in the journal often explores the underlying molecular and cellular mechanisms of lung diseases, including studies on gene expression, inflammation, and immune response. - Innovative Therapeutic Approaches:
The journal features studies on novel therapeutic strategies, including pharmacological interventions, biologics, and emerging therapies for various pulmonary conditions. - Public Health and Epidemiology:
The journal also emphasizes public health issues related to respiratory diseases, including studies on the impact of environmental factors, tobacco use, and healthcare disparities. - Patient-Centered Research:
There is a strong focus on patient-reported outcomes and quality of life, aiming to integrate patient perspectives into research and clinical care.
Trending and Emerging
- Personalized Medicine:
Emerging research focuses on tailoring treatments based on genetic, environmental, and lifestyle factors, particularly in conditions like asthma and pulmonary fibrosis, emphasizing the importance of individualized patient care. - Telemedicine and Remote Monitoring:
The COVID-19 pandemic has accelerated the adoption of telemedicine and remote patient monitoring technologies, leading to an increase in studies evaluating their effectiveness in managing chronic respiratory diseases. - Long-COVID and Post-Acute Sequelae:
There is growing attention on the long-term effects of COVID-19, including post-acute sequelae, with research exploring respiratory, cardiovascular, and neurological implications, highlighting the need for comprehensive care strategies. - Microbiome Research:
Increasing interest in the role of the lung microbiome in health and disease, particularly its impact on asthma, COPD, and pulmonary infections, is emerging as a significant area of research. - Innovations in Imaging Techniques:
Advancements in imaging technologies, such as machine learning applications in radiology and novel imaging biomarkers, are gaining prominence for their potential to enhance diagnosis and monitoring of lung diseases. - Environmental and Social Determinants of Health:
Research increasingly emphasizes the impact of environmental factors and social determinants on respiratory health, focusing on disparities and the need for community-based interventions.
Declining or Waning
- Traditional Diagnostic Methods:
There appears to be a decreasing emphasis on traditional diagnostic methods, such as bronchoscopies and lung biopsies, as newer, less invasive techniques and imaging modalities gain traction. - Basic Science without Clinical Correlation:
Research focusing solely on basic science without direct clinical implications or applications is becoming less prevalent, as there is a greater push for translational research that bridges laboratory findings to patient care. - General Pulmonary Rehabilitation:
While pulmonary rehabilitation remains important, there is a shift towards more specialized and targeted rehabilitation practices rather than general approaches, leading to a decline in studies focusing on broad rehabilitation protocols. - Conventional Pharmaceutical Approaches:
There is a noticeable reduction in studies promoting conventional pharmaceutical approaches, with more research being directed towards personalized medicine and biologic therapies. - Single Disease Focus:
Research that concentrates on single diseases, such as isolated studies on asthma or COPD without considering comorbidities, appears to be waning in favor of studies that examine the interplay between multiple conditions.
Similar Journals
Chronic Respiratory Disease
Fostering collaboration in respiratory health advancements.Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.
THORAX
Elevating respiratory research to new heights.THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.
Respiratory Care
Innovating Insights for Enhanced Patient Outcomes.Respiratory Care is a leading journal in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, published by DAEDALUS ENTERPRISES INC. With a history dating back to 1973 and continuing through 2024, this journal serves as a vital platform for disseminating innovative research findings, clinical practices, and advancements in respiratory healthcare. The journal is recognized for its impact, reflected in its impressive Q2 quartile rankings across several categories in 2023, demonstrating its relevance and influence in the medical community. Although it is not an Open Access publication, it provides critical insights and foster discussions aimed at enhancing patient care and treatment protocols for respiratory diseases. The journal is indexed in notable databases, ensuring wide visibility and accessibility of its content to researchers, professionals, and students dedicated to advancing knowledge and practice in respiratory care.
BMJ Open Respiratory Research
Elevating global discourse in pulmonary and respiratory research.BMJ Open Respiratory Research is a prestigious open access journal published by the BMJ Publishing Group, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2014, the journal has provided a vital platform for the dissemination of innovative research and clinical findings, boasting an impressive Q1 ranking in its category as of 2023. With a Scopus rank of #35 out of 155 in Pulmonary and Respiratory Medicine, BMJ Open Respiratory Research is recognized for its high-quality content, engaging a global audience of researchers, healthcare professionals, and students. The journal embraces an open access model, ensuring that groundbreaking research is readily available to the community and stakeholders, thereby accelerating knowledge exchange and improving patient care. By focusing on diverse aspects of respiratory health, this journal plays a crucial role in shaping the future of respiratory research and practice.
RESPIRATORY MEDICINE
Pioneering Research for Better BreathingRespiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.
Zeitschrift fur Pneumologie
Fostering Collaboration for Lung Health AdvancementZeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.
Turkish Thoracic Journal
Transforming the landscape of pulmonary medicine, one study at a time.Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.
Therapeutic Advances in Respiratory Disease
Elevating Standards in Pulmonary ResearchTherapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.
EXPERIMENTAL LUNG RESEARCH
Elevating Knowledge in Pulmonary and Respiratory MedicineEXPERIMENTAL LUNG RESEARCH, published by Taylor & Francis Inc, is a pivotal journal within the field of pulmonary and respiratory medicine, with its extensive coverage spanning from 1980 to 2024. The journal is indexed with ISSN 0190-2148 and E-ISSN 1521-0499, marking its commitment to disseminating high-quality research. With its Category Quartile rankings falling within Q3 in Clinical Biochemistry, Molecular Biology, and Pulmonary and Respiratory Medicine as of 2023, EXPERIMENTAL LUNG RESEARCH serves as a crucial platform for researchers and professionals seeking to explore innovative findings and advancements in lung physiology, pathology, and therapeutic approaches. Although currently not Open Access, it offers substantial insights through rigorous peer-reviewed articles that contribute significantly to the scientific community's understanding of respiratory health. With Scopus rankings reflecting its relevance within its categories, this journal attracts a diverse readership interested in advancing the field of lung research.
Egyptian Journal of Chest Diseases and Tuberculosis
Transforming knowledge into practice for better respiratory care.The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.